Medtronic announced financial results for the fourth quarter and full fiscal year on Thursday. Here are three things to know:

A strong finish to the fiscal year

The performance of several businesses – including many in the cardiovascular, neuroscience, and medical surgical portfolios – boosted sales during the fourth quarter. An increase in medical procedures, supply chain improvements, and introductions of innovative products helped, too.

Pipeline momentum

The Medtronic pipeline is strong and gaining momentum. The MiniMed™ 780G system with Guardian™ 4 sensor for people living with diabetes recently received U.S. Food and Drug Administration approval. The Affera™ mapping and ablation system – including our Sphere-9™ catheter – received CE Mark in March. And innovative technologies like our Micra™ leadless pacemaker continue to reach more patients.

Transforming for growth and looking ahead

Behind the scenes, Medtronic is working to deliver durable growth by investing in the right opportunities and executing well. The company increased its dividend for the 46^th consecutive year and announced its FY 2024 guidance.

L009-05242023

Related content

‘It lets me live my life’: Diabetes care milestone reached

Medtronic jumps to No. 2 in DiversityInc Top 50 Companies list

5 ways artificial intelligence is transforming healthcare